The main objective in cancer drug discovery programs is to rapidly identify lead compounds that have promising pharmacokinetics (PK) and pharmacodynamics (PD) (efficacy). However, screening of compounds for efficacy in animal models of cancer (xenograft and orthotopic models) takes approximately a month. Secondly, PK and PD studies are performed in different animals. Thirdly, efficacy is studied against different cell lines in different groups of animals
The hollow fibre (HF) model in mice provides a platform to rapidly screen anti-cancer compounds simultaneously for PK and efficacy against multiple cell lines to identify promising compounds for proof of concept studies in xenograft models. Efficacy in Hollow Fibre models has been shown to be predictive of efficacy in Xenograft models.
TheraIndx Lifesciences has established and validated the HF model. This model can be used to quickly screen promising anti-cancer compounds for PK/PD and prioritisation for Proof of concept studies in Xenograft models.